Brief: Vir Biotechnology Completes Enrollment Of Phase 2 Chronic Hepatitis Delta Solstice Trial
05/03/2024 13:48
March 5 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY COMPLETES ENROLLMENT OF PHASE 2 CHRONIC
HEPATITIS DELTA SOLSTICE TRIAL AHEAD OF SCHEDULE
* VIR BIOTECHNOLOGY INC - INITIAL DATA ARE EXPECTED IN Q2 OF
2024
Source text for Eikon: ID:nBw1kcbPYa
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO